explore -WSS

explore

author：fashion 2025-09-27 13:11:20 - browse：9154

portrait of Jennifer Adair -- coverage from STAT — Jennifer Adair develops scalable, low cost gene therapies at the Fred Hutchinson Cancer Center and helped found the Global Gene Therapy Initiative. Fred Hutch News Service

BALTIMORE — Gene and cell therapies have transformed a handful of devastating disorders in the U.S. and Europe, with more treatments on the way. But those technologies have largely failed to reach most of the world.

These lags are ubiquitous in the current drug development system, where new therapies are approved in wealthy countries and then slowly leak out to low- and middle-income countries, many years later. In the case of gene therapy, that means countries most affected by a disease such as sickle cell may wait decades to access a curative therapy.

For the last few years, a handful of researchers in the U.S. and around the world have tried to find ways of ensuring global access to these technologies. In 2020, they formed the Global Gene Therapy Initiative, with an initial goal of setting up a gene therapy clinical trial for a hemoglobinopathy — such as a disease like sickle cell or beta thalassemia — or HIV in two different low- and middle-income countries by 2024.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： As demand for Covid shots wanes, Moderna seeks its next success
Next article： Has Bernie Sanders reached the limit of his pharma bullying effort?

leisure time

WSS

Chemotherapy before breast cancer surgery might fuel metastasis

AI can decode, harness the power of the humane immune system

AI for drug discovery: Experts on separating hype from reality

Lawmakers grill UnitedHealth CEO on Change cyberattack

AltruBio raises $225 million to develop ulcerative colitis drug

The creative science of coining drug names

hotspot

explore

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Wikipedia

Continuity nursing helped my family in our darkest PICU moments

As billionaires fund anti

Hepatitis C has a cure — but many Americans still lack access to it

Was Amgen transparent enough on FDA's concern on cancer drug?

BioMarin wins approval for gene therapy to treat hemophilia A

As billionaires fund anti

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

GSK’s asthma push continues as drug succeeds in Phase 3 trials

Trump demands the U.S. pay no more for drugs than other countries … again

Eli Lilly buys Point Biopharma in radiopharmaceuticals play

Wikipedia

In $4.8 billion deal, Bristol Myers Squibb to buy cancer player Mirati

Brain MRIs reveal impact of 'toxic stress' on Black children

PBM executives asked to testify by House panel

As billionaires fund anti

Lawmakers grill UnitedHealth CEO on Change cyberattack

Chan Zuckerberg Biohub Chicago to focus on inflammation

hotspot

leisure time

leisure time

hotspot